BMAL2 CRISPR/Cas9 KO Plasmid (m): sc-435462

Overview

Arntl2 encodes BMAL2, a basic helix–loop–helix PAS transcription factor that heterodimerizes with CLOCK/NPAS2 to regulate E-box–driven gene expression and coordinate circadian and metabolic transcriptional programs in mouse tissues. BMAL2 influences core clock circuitry, rhythmic chromatin regulation, and downstream pathways including redox homeostasis, lipid and glucose metabolism, and cell-cycle timing through transcriptional control of clock-controlled genes. Dysregulation of ARNTL2/BMAL2-associated networks has been linked in the literature to altered inflammatory signaling, stress responses, and changes in cell migration and differentiation, making it relevant for mechanistic studies of circadian disruption. In vivo and cellular models implicate BMAL2 in tissue-specific clock output and adaptation to environmental cues, supporting its use in research on neurobiology, metabolism, and tumor-associated transcriptional states without implying clinical outcomes.

BMAL2 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Arntl2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Arntl2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Arntl2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish BMAL2 protein expression.

This CRISPR knockout system enables efficient generation of Arntl2-deficient cell models for investigation of BMAL2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

Key Features

• sgRNAs targeting Arntl2 exon(s) critical for BMAL2 function
• Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
• GFP reporter for identification of transfected cells
• Pool of plasmids targeting multiple Arntl2 genomic sites to improve knockout efficiency
• Compatible with delivery by transfection

Design Variants

CRISPRs +/- HDRs

• gRNAs encoded by BMAL2 CRISPR/Cas9 KO Plasmid (m) and BMAL2 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Arntl2 locus. One or both targeting designs may be available. See Related Products for availability.
• HDR donor constructs encoded by BMAL2 HDR Plasmid (m) and BMAL2 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Arntl2 homology arms to support homology-directed repair at defined Arntl2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.